photosensitizer

(redirected from Photosensitiser)
Also found in: Dictionary, Medical.

photosensitizer

[¦fōd·ō′sen·sə‚tīz·ər]
(physical chemistry)
A light-absorbing substance that initiates a photochemical or photophysical reaction in another substance (molecule), and is not consumed in the reaction.
References in periodicals archive ?
The PDT damage to HepG2 cells increased with increasing of the concentration of the photosensitiser and then plateaued at concentrations more than 25 [micro]g/ml.
OSLO -- PCI Biotech reported today that it has completed the treatment of the third dose group in the phase I/II study of its proprietary photosensitiser Amphinex[R] used in combination with the cytotoxic agent bleomycin in cancer patients.
The subject of the tender is the supply of accrued spectrofluorimeter, allowing luminescence detection with high temporal and spectral resolution, with emphasis on the possibility of direct detection of singlet oxygen (1270 nm) and singlet oxygen sensitized delayed fluorescence porfyrinoidnE[degrees]ch photosensitiser (600-700 nm).
17 March 2010 - Norwegian biopharmaceutical company PCI Biotech Holding ASA (OSL: PCIB) said yesterday it successfully completed the third dose group in its phase I/II trial with its proprietary photosensitiser Amphinex in combination with bleomycin in cancer patients.
Norwegian biopharmaceutical company PCI Biotech (Oslo:PCIB) declared on Tuesday the completion of the second dose group in the phase I/II study of its proprietary photosensitiser Amphinex used in combination with the cytotoxic agent bleomycin in cancer patients.
OL) (OSE:PCIB) reported today that it has completed the successful treatment of the second dose group in the phase I/II study of its proprietary photosensitiser Amphinex([R]) used in combination with the cytotoxic agent bleomycin in cancer patients.
Last month, PCI Biotech announced that strong anti-tumour response was observed in all patients from the second dose group in a phase I/II study of its proprietary photosensitiser Amphinex in the University College Hospital (UCH) in London.
19 January 2010 - Norwegian biopharmaceutical company PCI Biotech Holding ASA (OSL: PCIB) said today that strong anti-tumour response was observed in all patients from the second dose group in the phase I/II study of its proprietary photosensitiser Amphinex.
The photosensitiser may be applied topically or occasionally given systemically.